Valuation Vivos Therapeutics, Inc.
Stocks
VVOS
US92859E2072
Medical Equipment, Supplies & Distribution
|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 0.1337 USD | +0.91% |
|
+1.98% | -93.41% |
| 10-19 | Vivos Therapeutics Buys 11% of SOD Sciences, Gains 50% Stake in Diagnostic Test | MT |
| 09-29 | Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives | CI |
Company Valuation: Vivos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 51.78 | 9.251 | 14.89 | 25.27 | 18.25 | 2.69 | - |
| Change | - | -82.13% | 61% | 69.64% | -27.79% | -85.26% | - |
| Enterprise Value (EV) | 51.78 | 9.251 | 14.89 | 25.27 | 18.25 | 2.69 | 2.69 |
| Change | - | -82.13% | 61% | 69.64% | -27.79% | -85.26% | 0% |
| P/E | -2.34x | -0.39x | -1.12x | -1.93x | -0.98x | -0.1x | -0.16x |
| PBR | - | - | 36.9x | 3.18x | -12.7x | - | - |
| PEG | - | -0.05x | 0x | 0x | 0.15x | 0x | 0x |
| Capitalization / Revenue | 3.07x | 0.58x | 1.08x | 1.68x | 1.05x | 0.12x | 0.08x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.12x | 0.08x |
| EV / EBITDA | - | -0x | - | - | -0x | -0.14x | -4.86x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.13x | -0.22x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -24 | -26 | -11.14 | -2.22 | -2.07 | -1.342 | -0.8233 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 16.88 | 16.02 | 13.8 | 15.03 | 17.44 | 21.79 | 34.09 |
| EBITDA 1 | - | -24.36 | - | - | -18.58 | -18.72 | -0.554 |
| EBIT 1 | -20.38 | -25.03 | -17.3 | -11.17 | -19.89 | -20.41 | -12.34 |
| Net income 1 | -20.29 | -23.84 | -13.58 | -11.14 | -21.17 | -23.53 | -14.7 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 56.2500 | 10.0500 | 12.4400 | 4.2900 | 2.0300 | 0.1337 | 0.1337 |
| Nbr of stocks (in thousands) | 920 | 920 | 1,197 | 5,890 | 8,988 | 20,118 | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/28/24 | 3/31/25 | 4/15/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.1x | - | - | - | 2.69M | |
| 34.01x | 4.08x | 15.69x | 2.48% | 179B | |
| 23.84x | 4.68x | 16.31x | 1.17% | 118B | |
| 20.4x | 3.54x | 12.67x | 2.97% | 117B | |
| 31.64x | 3.06x | 12.36x | 2.24% | 93.26B | |
| 18.15x | 0.21x | 13.14x | 0.72% | 63.16B | |
| 31.42x | 7.87x | 20.23x | 1.26% | 55.68B | |
| 39.45x | 3.63x | 12.37x | 2.1% | 54.18B | |
| 37.95x | 9.42x | 26.36x | -.--% | 44.15B | |
| 40.74x | 3.29x | 12.28x | 0.53% | 33.95B | |
| Average | 27.75x | 4.42x | 15.71x | 1.5% | 75.84B | |
| Weighted average by Cap. | 29.45x | 4.16x | 15.26x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VVOS Stock
- Valuation Vivos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
